ArticleWorld journal of microbiology & biotechnology2020
Intracellular biosynthesis of PbS quantum dots using Pseudomonas aeruginosa ATCC 27853: evaluation of antibacterial effects and DNA cleavage activities.
Article in World journal of microbiology & biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Biogenic synthesis of PbS nanoparticles by Micrococcus luteus and their application in high-performance photodetectors.Scientific reports · 2025Article
- Microbial Fabrication of Quantum Dots: Mechanism and Applications.Current microbiology · 2024Review
- Review
- Biosynthesis of Quantum Dots and Their Therapeutic Applications in the Diagnosis and Treatment of Cancer and SARS-CoV-2.Advanced pharmaceutical bulletin · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Bacterial biosynthesis of quantum dots (QDs) offers a green alternative for the production of nanomaterials with superior properties, such as tunable size dependent emission spectra and a long fluorescence lifetime. In this study, we have achieved intracellular production of PbS QDs using Pseudomonas aeruginosa ATCC 27853. The characterization of these PbS QDS was performed by different techniques, such as Ultraviolet-visible (UV-Vis) spectroscopy, photoluminescence (PL), X-ray diffraction (XRD), transmission electron microscopy (TEM), energy dispersive X-ray analysis (EDX) and particle size analysis (DLS). The obtained results confirmed the synthesis of PbS QDs. The PbS QDs showed absorption peaks at 1088 nm (ultraviolet-visible spectrometry) and a luminescence peak at 1572 nm. In addition, the intracellular biosynthesized PbS QDs showed a particle size in the range 3.47-11.45 nm, which is consistent with DLS and sphere-shaped nanocrystals with good crystallinity and a cubic cristalline structure including pure Pb and S elements. Biosynthesized PbS QDs showed antibacterial activity against Proteus mirabilis ATCC 25933 and Escherichia coli ATCC 25922 from Gram (-) bacteria and Bacillus cereus NRLL B-3008 and Micrococcus luteus ATCC 10240 from Gram (+) bacteria. Besides, these current results obtained from the cleavage studies revealed that PbS QDs do not show DNA cleavage activity. Consequently, the microorganism-based intracellular method allows an economic and environmentally friendly way to obtain PbS QDs with superior optical properties and they have a potential to be used in healthcare applications.
Indexed as
Identifiers
32888099What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.